key: cord-0839001-pye5kqml
authors: Wu, Alan H B
title: Screening the general population for SARS CoV-2 virus and COVID-19 antibodies: a counter-argument
date: 2020-07-01
journal: J Appl Lab Med
DOI: 10.1093/jalm/jfaa104
sha: 2e240863e71c2dfd502cd8d5e5a1db5a15338621
doc_id: 839001
cord_uid: pye5kqml

nan

colleagues are working overtime to provide the necessary supplies, and I am confident that these shortages will be temporary. Once fully loaded, the principal question is: should there be a massive antigen and antibody screening program across America? Viral nucleic acid testing for the presence among asymptomatic individuals is more invasive and expensive than serum antibody testing. Nasopharyngeal sampling requires more skill and training to produce a good sample and to minimize false negative results. Healthcare workers are at high risk for contracting the virus from an infected patient. Transportation of samples from the point of collection to testing laboratories present additional infection control challenges. Point-of-care testing devices are available for RT-PCR that can detect the presence of SARS-CoV-2 in five minutes (2) . More studies are needed to compare the sensitivity of these platforms against central laboratory tests. Work is also underway for development of an immunoassay for a relevant SARS CoV-2 protein (antigen test). While this test will still require nasopharyngeal sampling, as the SARS CoV-2 virus content in blood is low, immunoassay testing is easier and less expensive than RT-PCR.

The prevalence of disease is an important issue for mass screening. The number of acute SARS-CoV-2 infection is currently unknown in the U.S., as individuals who were asymptomatic do not have access to virus testing. If it turns out that the prevalence is low, the clinical sensitivity of current virus tests will be inadequate for mass screening. While the clinical specificity of the RT-PCR test for SARS-CoV-2 is high, one study conducted in China reported clinical sensitivities of only 59% of 1014 patients (3) . False negative results could be caused by inadequate sampling or timing relative to the onset of the infection and symptoms. Sampling a cross-section of asymptomatic individuals for the virus will likely find very few cases, unless screening take place in the highly pandemic areas.

Detecting antibodies to SARS-CoV-2 is a better approach towards mass screening of asymptomatic subjects, as the window for detection will be much broader. Collecting and testing blood for the presence of COVID-19 antibodies in serum on a mass screening is easier than molecular testing for the virus. Moreover, there are point-of-care antibody testing devices that are available from a fingerstick blood sample that can produce results within 15 minutes. The sensitivity of antibody tests, however, will need to be high for this to be successful. Whitman et al. evaluated 10 lateral flow assays for COVID antibodies, testing devices likely to be used for screening (4) . On blood collected 21 days or more after disease onset, these investigators showed that for detecting either IgM or IgG antibodies, 9 out of 10 kits had a clinical sensitivity 90% or less. Use of these tests will also be inadequate for mass screening of a population with a low infection rate. For example, if only 10% of the general population has antibodies, use of a test with a 90% sensitivity and 90% specificity will produce an equal number of true positive and false positive results (see Table 1 ). More accurate tests and/or a higher a prevalence of a past infection will improve the utility of screening. Central laboratory assays for SARS-CoV-2 antibodies have been cleared/approved by the FDA, have higher clinical sensitivity and specificity, and would produce more favorable results for mass screening (5) . However, there may be a preference by agencies conducting screening to use POC tests because results can be made available immediately without sending samples to a clinical laboratory.

There is a second testing issue that will challenge the value of a mass screening program using antibody detection. An effective infection control program requires the demonstration that antibodies produced in blood are neutralizing against the virus. In general, antibodies can be produce to any of the SARS CoV-2 proteins include the spike protein, nucleoapsid protein, and membrane protein. Most of these proteins do not participate in the replication of the virus within the host. One study suggested that some individuals produce anti-COVID-19 antibodies that are not in fact neutralizing against the virus (6) . Most virologists believe that it is the receptor binding domain (RBD) of the spike protein binds to the angiotensin converting enzyme-3 receptor in order to gain entry to the cell (7) . Moreover, the spike protein must be "primed" by extracellular serine proteases so that the viral membrane protein can fuse with the host cell enabling virus entry (8) . The gold standard for determining if a serum antibody is neutralizing is the plaque-reduction neutralization test (PRNT) (9) . Experimental cells are treated with serum containing anti-virus antibodies from patient sera and then live virus is added. If these antibodies can inhibit transfection, they are considered neutralizing. One recent study correlated antibody results from COVID-infected patients against the PRNT (6). They reported correlation coefficients ranging from r=0.42 to 0.51 when the capture antibody used in the immunoassay was the S1, S2 subunits and the RBD of the spike protein. These results suggest that some patients produce neutralizing antibodies but do not result in a positive COVID-19 antibodies response (false negative). In this situation, the immunoassay is detecting the wrong antibody.

Other patients have COVID-19 antibodies but they cannot neutralize a viral infection (false positive). It is possible that the antibodies produced in these patients were directed towards a viral protein that is not essential for its replication. In the haste of producing COVID-19 antibody test, and the laxing of the FDA approval through Emergency Use Authorization, the quality and reliability of these assays may be substandard. A next generation antibody test is required that has higher correlation to virus neutralization. I am not in favor of mass screening of the general population using the current virus and antibody assays. The COVID-19 pandemic has eased in many parts of the world where the pandemic first started, with a return of citizens to their pre-pandemic activity levels. Some of these countries have experienced a second wave of infections (10) . How many lives are we prepared to sacrifice to stimulate to nation's economy? If I lost my job because of COVID-19, I probably would take risks needed to provide for my family, as would most others. Fortunately, as healthcare workers, our occupation is secured and we are not faced with making these difficult decisions. However, promoting dangerous medical practices is against the fabric of our occupational existence. If we are going to release COVID antibody testing on a continental or even global scale, let us at least educate the public regarding the information they are receiving. 

Insight into FDA's revised policy on antibody tests: prioritizing access and accuracy

Comparison of Abbott ID Now, Diasporic Simplex, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasoparyngeal and nasal swabs from individuals diagnosed with COVID-19

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Test performance evaluation of SARS-CoV-2 serological assays

EAU authorized serology test performance

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Characterization of the receptorbinding domain (RBD) of 2019 novel coronavirus: implications for development of RBD protein as a viral attachment inhibitor and vaccine

SARS-CoV-2 cell entry depends on ACD3 and TMPRSS# and is blocked by a clinicaly proven protease inhibitor

Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance

Beware of the second wave of CIVID-19